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Abstract
Cardiovascular diseases (CVDs) are the main causes of mortality and disability worldwide. Although the initial therapeutic 
approach to improve the main cardiovascular (CV) risk factors is based on nonpharmacological measures, mainly lifestyle 
modifications, compliance to recommendations is often poor and inadequate. Therefore, in recent years the use of several 
nutraceuticals, i.e., nutrients and/or bioactive compounds of plant or microbial origin with potentially healthful effects, 
has become widespread. However, to date, the scientific data on the possible benefits of the use of nutraceuticals are still 
inconclusive, due to the absence of adequately controlled intervention studies at least for some of them. Against this back-
ground, the scientific evidence derived from controlled intervention studies in relation to the effects of some nutraceuticals 
(i.e. fiber, phytosterols, soy products, red yeast rice, polyphenols and berberine) on the main CV risk factors (body weight, 
blood pressure, blood glucose levels and plasma lipids) in humans will be reviewed.
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1 Introduction
Cardiovascular diseases (CVDs), including coronary heart 
disease and stroke, are the main causes of mortality and dis-
ability both largely preventable through the control of risk 
factors via lifestyle modifications and preventive medication.
The initial therapeutic approach to the main risk factors 
for CVDs should always include nonpharmacological meas-
ures—such as lifestyle interventions, which are very similar 
for all CV risk factors [1]. In fact, current recommenda-
tions strongly encourage the reduction of total energy intake 
from foods and the increase in physical activity, especially 
in overweight/obese individuals. Moreover, saturated fat 
should be limited to less than 10% of calories, saturated 
and trans fatty acids should be replaced with polyunsatu-
rated (PUFA) (up to 10% of calories) or monounsaturated 
(MUFA) fatty acids (10–15% of calories), and dietary fiber 
intake should be increased (30–45 g/day). Daily salt intake 
also should be reduced by at least one third and, if possible, 
to < 5 g per day. Moreover, dietary patterns that include a 
variety of fruits, vegetables, seeds and nuts (2–3 servings of 
each per day), pulses and whole grains are strongly encour-
aged, to promote health and lower CVD risk [2, 3].
However, adherence to lifestyle modification to prevent 
CVDs is often poor due to unsatisfactory patient compli-
ance and poor adherence and maintenance in the medium- to 
long-term [4]. In addition, some dietary components with a 
potentially beneficial activity on CV risk factors are present 
only in scanty amounts in food. Therefore, the use of nutra-
ceuticals has become widespread in recent years.
Nutraceuticals are nutrients and/or bioactive compounds 
of plant or microbial origin, with possible beneficial effects 
on human health when supplemented in adequate amounts 
(often above those present in foods). Nutraceuticals may be 
added to different foods and beverages (as in fortified foods), 
or taken in the form of dietary supplements (liquid prepara-
tions, tablets, capsules).
A growing number of nutraceuticals with variable activity 
on different CV risk factors have been proposed; unfortu-
nately, scientific research has produced conflicting results 
for some of them. Hence, the aim of this report is to review 
and discuss the scientific evidence derived from controlled 
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intervention studies regarding the effects of some nutra-
ceuticals (i.e. fiber, phytosterols, soy products, red yeast 
rice, polyphenols and berberine) on the main CV risk fac-
tors (body weight, blood pressure, blood glucose levels and 
plasma lipids) in humans.
2  Effects on Body Weight
Overweight and obesity are currently recognized as the 
major risk factors for the development of a number of 
chronic diseases, including diabetes, dyslipidemia, CVDs 
and some types of cancer. Due to the dramatic increase in 
obesity prevalence, researchers have attempted to find effec-
tive complementary therapies for obesity and its complica-
tions, thus identifying in the supplementation of some nutra-
ceuticals, mainly fibers and polyphenols, a potential tool and 
strategy to facilitate body weight management and influence 
obesity associated CV risk factors.
2.1  Fiber
The overall evidence from clinical intervention studies 
indicates soluble/viscous fibers as the most effective sup-
plements for the management of body weight. Previous 
meta-analyses of twelve randomized controlled trials (RCTs) 
evaluated the effects of supplementation of different types 
of isolated soluble fiber (manno-oligosaccharides, galacto-
oligosaccharides, fructo-oligosaccharides, β-glucan, flax-
seed mucilage, mannans and dextrin) on outcomes related to 
weight management. Overall, the results showed that, inde-
pendently of energy restriction or weight loss counseling, 
soluble fiber supplementation, compared to placebo, signifi-
cantly reduced Body Mass Index (BMI) by 0.84 kg/m2, body 
weight by 2.52 kg and body fat by 0.41% in overweight and 
obese adults, at a mean dose of 18.5 g/day, over a follow-
up of 2–17 weeks [5]. In line with this trend, findings from 
a three-arm, parallel, blind RCT on 83 overweight/obese 
individuals, showed that the supplementation of a com-
mercial soluble viscous non-starch polysaccharide complex 
(PolyGlycoplex-PGX, as softgels or granules), containing 
konjac glucomannan, sodium alginate and xanthan gum, for 
12 weeks, led to a significant reduction in waist circumfer-
ence (− 2.5 cm) in the whole study population, as well as 
a to significant decrease in body weight (− 1.4 kg) in the 
subgroup of participants who consumed the recommended 
dose of fiber (about 12.2 g/day) [6].
Isolated glucomannan is also effective in the management 
of body weight [7, 8]. In fact, results from a glucomannan-
focused meta-analysis of 14 RCTs showed a statistically sig-
nificant, albeit small, reduction in body weight, of 0.79 kg in 
studies lasting a mean of 5.2 week [7]. However, the benefits 
observed with glucomannan supplementation on weight loss 
were not independent of the dietary modifications imple-
mented in these RCTs. These findings have been confirmed 
by a meta-analyses of only 6 RCTs, in overweight/obese 
individuals, reporting a significant effect of glucomannan 
supplementation on body weight at different points dur-
ing the intervention periods: at week 2 (− 0.21 kg), week 
4 (− 2.04 kg) and week 5 (− 1.3 kg), at an average dose of 
glucomannan between 1.24 and 3.99 g/day [8].
The positive effect of glucomannan supplementation 
on the reduction of body weight was already confirmed in 
2010 by the European Food Safety Authority (EFSA). The 
effect claimed is achieved when ≥ 3 g of glucomannan is 
supplemented daily in three 1-g doses, together with one to 
two glasses of water before the meal, in the context of an 
energy-restricted diet.
Other types of soluble fiber supplements, such as psyl-
lium, dextrin and alginate, in combination with an energy 
restriction program, have proven capable to affect body 
weight and body composition and thus to be of some help 
in the management of obesity [9–11].
In conclusion, based on the available evidence in humans, 
it seems that soluble/viscous fiber supplements may be help-
ful in the management of body weight; it is nevertheless 
important to underline that the significant reduction in body 
weight observed in many studies is of small entity.
2.2  Polyphenols
Among polyphenols, flavonoids appear to be the most 
involved in obesity and weight management. In particular, 
epigallocatechin-3-gallate (EGCG), mainly abundant in 
green tea, represents the subclass of flavonoids best associ-
ated with weight loss.
Some years ago, Basu and colleagues [12], in a clinical 
trial in obese people, showed that an 8-week supplementa-
tion of encapsulated green tea extracts, containing 870 mg of 
catechins, resulted in a statistically significant reduction in 
body weight and BMI, by 1.9 kg and 0.6 kg/m2, respectively, 
compared to placebo. The results of two other randomized 
controlled trials performed with either encapsulated green 
tea extracts (800 mg catechins) for 8 weeks or decaffeinated 
green tea extracts (EGCG 856.8 mg) for 12 weeks confirms 
the results obtained by Basu [13, 14].
Conversely, other clinical studies have failed to show a 
beneficial effect of green tea catechin supplements on body 
weight and/or body composition. There may be different rea-
sons for these discrepancies, one of which may be related 
to the possible confounding effect of caffeine. In fact, green 
tea extract naturally contains caffeine, a component known 
to influence per se body weight and body composition by 
enhancing sympathetic nervous system activity and regulat-
ing appetite [15]. Therefore, as a metabolic stimulant, the 
concentration of caffeine in green tea extract supplements 
The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease
should be carefully examined in relation to the independ-
ent effects of catechins on body weight. To this regard, a 
meta-analysis of 15 RCTs tried to characterize the relation 
between green tea catechins with and without caffeine, with 
changes in anthropometric parameters in overweight/obese 
people. This meta-analysis showed that the supplementa-
tion of catechins with caffeine, at a dose ranging from 583 
to 714 mg/day over a median period of 12 week, decreased 
body weight, BMI and waist circumference by 1.38 kg, 
0.55 kg/m2 and 1.93 cm, respectively, compared with a 
caffeine-matched control [16]. On the other hand, the few 
studies included in this meta-analysis on effects of catechins 
without concomitant caffeine administration did not show 
benefits on any of the anthropometric endpoints assessed.
In conclusion, results from RCTs evaluating the effect of 
tea catechin supplementation on outcomes related to obesity 
management are still discordant and inconclusive. Several 
confounding factors can influence the results of the available 
clinical trials, such as the concomitant presence of caffeine, 
but also the ethnicity of participants (Asians seems to be 
more responsive to caffeine) and the implementation or not 
of weight loss strategies.
2.3  Omega‑3 Polyunsaturated Fatty Acids (n‑3 
PUFAs)
Based on studies performed in animals some years ago, 
it has been hypothesized that n-3 PUFA supplementation 
could influence body weight regulation to some extent, by 
increasing body fat oxidation or energy expenditure [17]. 
Instead, the evidence from RCTs in humans is limited and 
very inconsistent. Findings from a meta-analysis of 11 RCTs 
in overweight/obese adults, showed that n-3 PUFA supple-
mentation, at a mean range dose of 1.5–6.0 g/day for 3 to 
24 weeks, has no effects on body weight and/or BMI, com-
pared to placebo. However, a subgroup analyses of only 7 
studies included in this meta-analysis, revealed a significant 
reduction in waist circumference after n-3 PUFA supple-
mentation compared to placebo [18]. In line with these find-
ings, more recently Jacobo-Cejudo and colleagues [19], in a 
randomized, single-blind, placebo-controlled pilot study in 
type 2 diabetic patients, showed that the supplementation of 
520 mg of docosahexaenoic acid (DHA) + eicosapentaenoic 
acid (EPA) fish-oil in the form of 2 soft gels per day for 
24 weeks, resulted in a 3.3 cm reduction in waist circumfer-
ence, compared to baseline values—but not vs. the placebo 
group—without affecting body weight, BMI and body fat. 
Furthermore, the supplementation of n-3 PUFA seems to 
be more effective in the reduction of body fat if associated 
with regular physical exercise and within the context of low 
calorie diets, even if the results are not univocal [20, 21].
In conclusion, the overall evidence from RCTs regarding 
the effect of n-3 PUFA supplementation on body weight 
reduction is very limited and, if anything, seems to suggest 
only a small effect on body fat reduction and distribution.
3  Effects on Blood Pressure
High blood pressure (BP) is one of the most relevant inde-
pendent risk factors for CVDs and the most prevalent all 
over the world. The major international guidelines have 
stressed the preventive impact of dietary and life-style inter-
vention in order to reach and maintain optimal BP levels [22, 
23]. Given the difficulties in implementing dietary changes, 
nutraceuticals have been considered a useful option.
3.1  Fiber
The overall body of evidence on the effect of fiber supple-
ments on BP is not very conclusive, at least for some types 
of fiber. A meta-analysis of 24 RCTs showed that fiber sup-
plementation (11.5 g/day) significantly reduced BP, but did 
not analyze the effects according to type of fiber [24].
Instead, Evans and colleagues [25], performed a detailed 
analysis of RCTs focusing on the effects of fiber with differ-
ent chemical structure, on BP in healthy populations. The 
authors found that diets rich in β-glucans, provided as oat 
bran, oat meals or oat beta-glucan-soluble powder—com-
pared with wheat-based control products, reduced systolic 
blood pressure (SBP) by 2.9 mmHg (95% CI 0.9–4.9) and 
diastolic blood pressure (DBP) by 1.5  mmHg (95% CI 
0.2–2.7), with a median difference in beta-glucans of 4 g, 
whereas little or no statistical evidence of impact on BP of 
the other types of dietary fiber was found.
More recently, another meta-analysis of RCTs evaluated 
the BP effects of different types of viscous fiber supplemen-
tation (β-glucan from oat and barley, guar gum, konjac, pec-
tin and psyllium) in healthy and hypertensive individuals 
[26]. Overall, the results showed that viscous fiber reduced 
SBP (− 1.59 mmHg) and DBP (− 0.39 mmHg) at a median 
dose of 8.7 g/day (1.45–30 g/day) over a median follow-up 
of 7 weeks. Within the fiber types, SBP reductions were 
observed for psyllium fiber supplementation [− 2.39 mmHg 
(95% CI − 4.62, − 0.17)], while for beta-glucan, which also 
has highly viscous properties, only a trend to SBP and DBP 
reductions was observed. Moreover, hypertensive subjects 
seem to be more responsive to viscous fiber supplements.
The overall findings demonstrate a modest but significant 
reduction in SBP and DBP following viscous soluble fiber 
supplementation, in particular beta-glucans and psyllium.
3.2  Polyphenols
Different studies in humans support the hypothesis that 
some polyphenols are able to exert favorable effects on BP. 
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A meta-analysis conducted by Zhang et al. [27] showed 
that grape seed extracts (100–2000 mg/day), rich in flavo-
noids, resveratrol and phenolic acids, supplemented for a 
mean period of 8 weeks can reduce SBP in obese subjects 
(WMD = − 4.469; 95% CI − 6.628, − 2.310; P < 0.001) and 
in patients with metabolic syndrome (WMD = − 8.487; 95% 
CI − 11.869, − 5.106; P < 0.001).
As for flavanol-rich cocoa products, two meta-analyses 
of RCTs revealed a significant reduction in SBP (− 4.5 or 
− 3.2 mmHg, respectively) and DBP (− 2.5 or − 2.0 mmHg, 
respectively) following cocoa flavanol intake ranging from 
30 to 1000 mg/day in short-term trials of 2–18 week dura-
tion [28, 29]. Particularly, the meta-analysis from Ried et al. 
[29] indicated that the hypotensive effect is present in hyper-
tensive and prehypertensive groups and not in normotensive 
groups.
A recent meta-analysis showed that in hypertensive 
patients soy isoflavone intake is associated with reduction 
in SBP by − 5.94 (95% CI − 10.55, − 1.34 mmHg, P = 0.01) 
and DBP by − 3.35 (95% CI − 6.52, − 0.19 mmHg, P = 0.04) 
[30]. As for healthy subjects, daily ingestion of 25–375 mg 
soy isoflavones (aglycone equivalents) for 2–24  weeks 
significantly decreased only SBP by 1.92 mmHg (95% CI 
− 3.45, − 0.39; P = 0.001) compared with placebo [31].
3.3  Omega‑3 Polyunsaturated Fatty Acids (n‑3 
PUFAs)
There is a wealth of data on the BP-lowering effect of n-3 
PUFAs. A recent meta-analysis of 70 RCTs showed that 
the consumption of omega-3 PUFAs (0.3–15 g/day) for 
4–26 weeks reduced SBP by 4.5 mmHg (95% CI − 6.1, 
− 2.8) and DBP by 3.0 mmHg (95% CI − 4.3, − 1.7), in 
untreated hypertensive individuals [32]. The hypoten-
sive effect is significant also in normotensive individuals, 
albeit to a more modest extent (SBP − 1.25 mmHg; DBP 
− 0.62 mmHg). These results are in line with those from 
two previous meta-analyses of RCTs showing that omega-3 
PUFA supplementation (≥ 3 g/day) for over 2 weeks was 
associated with an improvement in SBP and DBP [33, 34], 
again more evident in hypertensive patients. On the other 
hand, type 2 diabetic patients are not responsive to omega-3 
supplementation for what concerns blood pressure [35].
Finally, based on current knowledge, EFSA has estab-
lished that an intake of about 3 g/day of EPA and DHA are 
required to obtain the claimed effect on blood pressure.
3.4  Red Yeast Rice, Berberine and Coenzyme Q10
There is very limited evidence in the literature on the effect 
of red yeast rice (RYR), berberine and coenzyme Q10 on 
BP. As for RYR, a meta-analysis of RCTs—most of which 
with low methodological quality—has shown that RYR + 
conventional therapy has no significant BP-lowering effect 
compared to placebo + conventional therapy in hypertensive 
subjects [36].
On the other hand, a meta-analysis of RCTs with ber-
berine suggests that the addition of the latter to life-
style intervention can be effective in reducing BP (SBP: 
MD = − 5.97 mmHg, 95% CI (− 9.19, − 2.74), P = 0.0003; 
DBP: MD = − 2.69  mmHg, 95% CI (− 5.06, − 0.31), 
P = 0.03) compared to lifestyle intervention alone or pla-
cebo [37]. The same positive effect on BP has been observed 
with berberine + hypotensive drug vs the same hypotensive 
drug (SBP: MD = − 4.91 mmHg, 95% CI (− 8.72, − 1.1), 
P = 0.01; DBP: MD = − 2 mmHg, 95% CI (− 3.76, − 0.24), 
P = 0.03) [37].
Data on the possible effect of coenzyme Q10 on BP are 
very discordant. In fact, while a previous meta-analysis con-
cluded that coenzyme Q10 has the potential to lower SBP 
by up to 17 mmHg and DBP by up to 10 mmHg in hyper-
tensive patients [38], a more recent one clearly showed no 
significant effect either on SBP or DBP when only controlled 
studies vs placebo (only two studies) were considered [39].
4  Effects on Blood Glucose Levels
Fasting and postprandial hyperglycemia is associated with 
increasing risk of CVDs and mortality among patients with 
abnormal glucose metabolism and in healthy population 
[40–42]. Therefore, treatment strategies to reduce blood 
glucose either at fasting or in the postprandial state become 
crucial to reduce the risk of CVDs.
A growing number of nutraceuticals with variable glu-
cose lowering activity have been proposed as a quite novel 
approach to treat hyperglycemia, although the scientific 
research on their use has produced conflicting results and 
the reliability of a number of trials has been flawed by meth-
odological limitations.
4.1  Fiber
Data from clinical trials seem to suggest that soluble fiber 
supplementation significantly reduces blood glucose levels, 
especially in the postprandial state, in subjects with pre-
diabetes and in patients with diabetes. The glucose-lowering 
effect of this type of fiber ranges from 7 mg/dl (for glu-
comannan) to 45 mg/dl (for psyllium, in the postprandial 
state), with possible variations in relation to the doses used 
in the different trials [5, 43–45].
Although most intervention trials with fiber supplements 
are of short duration and performed on small groups of sub-
jects, the results are quite consistent, especially for β-glucans 
and pectin. In fact, based on current knowledge, these types 
of fiber have been the object of a specific claim by EFSA for 
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the maintenance of optimal postprandial glucose levels at a 
dosage of 4 g for each 30 g of available carbohydrates for 
β-glucans, and 10 g for meal for pectin.
4.2  Polyphenols
Epidemiological and clinical studies support the favorable 
effects of polyphenol-rich diets, characterized by a higher 
amount of polyphenols from cereals, fruit, vegetables, cof-
fee, tea, and chocolate, in preventing diabetes and in improv-
ing blood glucose levels [46–49].
Against this background, in recent years, the possible glu-
cose-lowering effect of different types of polyphenols added 
to the habitual diet is raising increasing interest. Two meta-
nalysis of randomized controlled trials indicate that flavan-
3-ols, present in green tea, green tea extracts, and chocolate, 
improve glucose metabolism (significant decrease in fasting 
blood glucose and glycosylated hemoglobin), and that this 
effect is caffeine-independent and more evident with higher 
doses of epigallocatechin (from 230 to 1200 mg/day) [50, 
51]. Similar effects appear to be present for soy isoflavones. 
In fact, along the same line, a metanalysis of few interven-
tion studies has shown that soy isoflavones—in particular 
genistein at 40–160 mg/day—significantly reduce fasting 
blood glucose and serum insulin although this effect is very 
limited from clinical point of view and present only in post-
menopausal women [52].
A small number of intervention studies evaluated the sup-
plementation of phenolic compounds derived from extra-
virgin olive oil and olive leaves, i.e., oleuropein (at a mean 
dose of 51.1 mg/day) and hydroxytyrosol (at a mean dose of 
9.7 mg/day); the results are quite promising, as they show a 
significant decrease in fasting blood glucose and glycosylate 
hemoglobin, but the evidence is still too scant for any con-
clusion to be drawn [53, 54].
Finally, some studies on resveratrol—one of the most 
studied phenolic compounds, largely present in grape 
peels—seem to support its hypoglycemic action, showing 
a decrease in glycemia, hemoglobin and insulin, but only in 
people with diabetes [55].
In conclusion, although the results of some interven-
tion studies seem to suggest a possible hypoglycemic effect 
related in particular to some types of polyphenols used as 
supplements, they must be confirmed by longer-term trials 
on larger population before recommendations may be given. 
Actually, up to now no claims have been released for poly-
phenols regarding the modulation of glucose metabolism.
4.3  Berberine
Berberine is an isoquinoline plant alkaloid present in sev-
eral plants, used since many years in China for its different 
therapeutic properties.
To date, studies in type 2 diabetic patients, and metanaly-
sis of these studies show that a dose of berberine between 
0.5 and 1.5 g/day for 8–12 weeks reduces fasting and post-
prandial blood glucose as well as HbA1c either when used 
alone or in combination with oral hypoglycemic agents [56]. 
Similar effects have been observed in subjects with meta-
bolic syndrome, in whom berberine administration induced 
a 36% remission of the presence of metabolic syndrome, 
decreased waist circumference, systolic blood pressure, TG, 
glucose levels and insulin secretion, and increased insulin 
sensitivity [57].
While berberine seems to be effective in improving blood 
glucose levels, some limitations need to be considered: (1) 
the evidence comes mainly from studies carried out in 
Asians, at least for the use of berberine alone, and it is not 
transferable to other ethnic groups, (2) no data is as yet avail-
able on the long-term safety of its use.
In fact, so far, neither EFSA nor FDA has yet released 
specific claims on the efficacy and safety of berberine.
4.4  Combination of Nutraceuticals
Nutraceutical combinations have been used as therapeutic 
strategies, especially for patients whose lipid and glucose 
levels were marginally high, but not to the extent as to war-
rant the prescription of either lipid- or glucose-lowering 
medications. A combination of nutraceuticals containing red 
yeast rice, berberine, policosanol, astaxanthin, Coenzyme 
Q10 and folic acid has been reported to be effective in reduc-
ing glucose levels, although the magnitude of the reduction 
varied across trials, the difference partly ascribable to differ-
ent durations and sample sizes of trials exploring lipid- and 
glucose-lowering effects of such combination [58, 59].
5  Effects on Plasma Lipids
Dyslipidemia, in particular high LDL-cholesterol (LDL-C) 
concentrations, are considered one of the main CV risk fac-
tors [60]. Lifestyle and different drugs are very effective in 
optimizing lipid profile. However, in some conditions and in 
some individuals, nutraceuticals as “pharmaceutical-grade 
nutrients” could represent a potentially useful tools to reduce 
LDL-C and optimize the overall plasma lipid profile in the 
general population as well as in people at high CV risk—in 
the latter cases in addition to the pharmacological therapy.
5.1  Fiber
Pirro et al. recently summarized the evidence from rand-
omized controlled trials, analyzing the results of relevant 
meta-analyses [61]. The LDL-C-lowering effect of fiber 
ranges from − 6 mg/dl (β-glucan and chitosan) to − 22 mg/
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dl (guar gum) in both healthy subjects and in patients with 
either hypercholesterolemia or diabetes. The effect of fiber 
supplementation on triglycerides (TG) and HDL-cholesterol 
(HDL-C) is less clear, even if a reduction of TG concen-
trations (− 11 mg/dl) has been observed for chitosan and 
glucomannan [61].
Based on current evidence, some fibers obtained a claim 
by FDA (β-glucan and psyllium) and by EFSA (β-glucan, 
chitosan, glucomannan, guar gum, hydroxypropylmethylcel-
lulose and pectin) for the maintenance of optimal LDL-C 
concentrations. EFSA has stated the effectual amount for the 
specific fibers as follow: β-glucan ≥ 3 g/day, chitosan 3 g/
day, glucomannan 4 g/day, guar gum 10 g/day, hydroxypro-
pylmethylcellulose 5 g/day and pectin 6 g/day [61].
5.2  Polyphenol
During the last decades, there has been substantial interest 
in the potential role of polyphenols in the modulation of 
lipid metabolism.
The main evidence comes from studies exploring the 
hypolipidemic effect of cocoa polyphenols (flavan-3-ols). 
Overall, the results of meta-analyses of randomized con-
trolled trials show that cocoa polyphenols (from 166 to 
2110 mg/day) significantly affect LDL-C, HDL-C and TG 
concentrations although with very limited effects from a 
clinical point of view [51, 62, 63]. As for tea polyphenols 
(flavan-3-ols), the current evidence is not conclusive due to 
the small number of high quality trials and the variability in 
dosage, exposure and study population [64–68]. However, 
the overall findings suggest that green tea may have greater 
effect than black tea, at least on LDL-C concentrations, due 
to the higher amount of catechins. As a matter of fact, the 
consumption of green tea beverages or extracts (from 145 to 
3000 mg/day of catechins) significantly reduced LDL-C by 
2.19 mg/dl [64, 65]. Conversely, similar amounts of black 
tea failed to show a hypocholesterolemic activity in any of 
the meta-analyses performed [66, 67]. None of the meta-
analyses showed any effect on HDL-C [64–68] or TG con-
centrations [68].
Looking at other specific phenolic compounds, a recent 
meta-analyses on quercetin supplementation has shown to 
significantly reduce LDL-C and TG (− 5 mg/dl and − 7 mg/
dl, respectively), and to increase HDL-C concentrations 
(2 mg/dl) even if these effects might not be clinically rel-
evant [69]. However, a previous meta-analysis showed 
a meaningful reduction of triglycerides concentrations 
(− 24.54 mg/dl) when more than 500 mg/day of quercetin 
were supplemented. Greater effect on LDL-C were observed 
for anthocyanin supplementation in both healthy [70] and 
dyslipidemic subjects [71] (− 14 mg/dl and − 22 mg/dl, 
respectively). Moreover, anthocyanins reduced TG (26 mg/
dl) and increased HDL-C (6 mg/dl) in dyslipidemic subjects 
[71], whereas no effect on these parameters was detected in 
healthy subjects [70]. For resveratrol, one of the phenolic 
compounds mostly studied, the current evidence does not 
support its hypolipidemic action (with resveratrol doses 
ranging from 8 mg/day to 1500 mg/day) [72, 73].
Finally, the results of a meta-analyses have shown that 
isoflavone extracts (on average 15 mg/day) seem to effec-
tively reduce TG concentrations (− 41 mg/dl) in patients 
with hypercholesterolemia, whereas no variations in LDL-C 
and HDL-C were observed [74].
Due to the limited clinical evidence, no claims have so 
far been released for polyphenols for the modulation of 
lipid concentrations. However, it should be pointed out that 
hydroxytyrosol and its derivative (oleuropein and tyrosol) 
have received a claim for the protection of LDL particles 
from oxidative damage (effective dose 5 mg/day), likely sug-
gesting that polyphenol may exert cardioprotective effects 
through mechanisms other than modulation of lipoprotein 
metabolism.
5.3  Omega‑3 Polyunsaturated Fatty Acids (n‑3 
PUFAs)
There is growing evidence supporting the beneficial effects 
of omega 3 supplementation (2–3 g/day) on TG (− 20 mg/dl 
on average), particularly among people with more elevated 
baseline concentrations [75–78]. In some of these interven-
tion studies, the decrease in TG was accompanied by a slight 
increase in LDL-C [79], while, on the whole, no effect on 
HDL-C has been consistently reported.
Based on current evidence, omega 3 supplementation 
(2–4  g/day) is recommended by the main international 
guidelines for the treatment of hypertriglyceridemia, and in 
addition to lifestyle changes and statin use in people with TG 
concentrations ranging from 200 to 500 mg/dl [80]. EFSA 
released a claim for 2 g/day of EPA and DHA to obtain 
the maintenance of normal fasting blood concentrations of 
triglycerides.
5.4  Phytosterols
Clinical studies and meta-analyses have demonstrated that 
phytosterols consumption (2–3  g/day) induces a mean 
10%-reduction of LDL-C in healthy subjects and in patients 
with hypercholesterolemia and/or diabetes, with little or no 
effects on HDL-C and TG [61].
Due to the consistent evidence, FDA and EFSA endorsed 
a claim related to the use of phytosterols for LDL-C reduc-
tion. However, EFSA recommended not to exceed a dose of 
3 g/day to prevent sitosterolemia (a rare autosomal reces-
sive disease characterized by phytosterol accumulation), and 
suggests that patients receiving lipid-lowering medications 
should use phytosterols under medical supervision [61].
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5.5  Red Yeast Rice
The hypolipidemic action of monacolin K, a natural ana-
logue of lovastatin produced by the Monascus purpureus-
fermentation of red rice, has been proven by meta-analy-
ses of clinical trials carried out in healthy subjects and in 
patients with dyslipidemia, diabetes, coronary heart disease 
or hypertension [61]. The reduction of LDL-C was − 30 mg/
dl on average for a mean monacolin k supplementation of 
10 mg/day. With the same amount of monacolin K, an 
hypotriglyceridemic effect was observed (− 26 mg/dl on 
average), whereas no influence on HDL-C was detected.
The amount of 10 mg/dl of monacolin K from red yeast 
rice has received the claim for the maintenance of normal 
LDL-C concentrations from EFSA and FDA [61].
However, it must be taken into account that monacolin 
K should have the same restrictions as lovastatin, accord-
ing to an FDA warning. Moreover, the Joint Commission of 
Experts of the Federal Office of Consumer Protection and 
Food Safety and the Federal Institute for Drugs and Medi-
cal Devices in Germany have stated that products provid-
ing 5 mg/day of monacolin K should be classified as drugs 
since they have a significant pharmacological action. In this 
regard, very recently, EFSA has concluded that “the avail-
able information on the adverse effects reported in humans 
was judged to be sufficient to conclude that monacolins from 
red yeast rice when used as food supplements were of sig-
nificant safety concern at the use level of 10 mg/day” [81].
5.6  Berberine
To date, evidence of a lipid-lowering effect of berberine 
comes mainly from studies carried out in Asian populations 
and cannot be easily extrapolated to other ethnic groups. 
Nevertheless, the main findings considered in three meta-
analyses [61] show that berberine (0.5–1.5 g/day) lowers 
LDL-C and TG concentrations (on average − 22 mg/dl and 
37 mg/dl, respectively), while beneficially increases HDL-C 
(on average 2 mg/dl).
So far, neither EFSA nor FDA have released specific 
claims on the efficacy of berberine.
5.7  Soy Protein
Soy protein has been largely investigated, even if it is not 
easy to evaluate its hypolipidemic effect independently of 
the isoflavone content. Overall, the evidence suggested that 
soy protein may improve lipid metabolism, affecting par-
ticularly LDL-C, but the extent of these effects is not at all 
conclusive [61]. Furthermore, soy protein seems to act only 
in individuals with high baseline LDL-C concentrations 
for whom other pharmacological therapies are now more 
indicated.
No claims for soy protein and lipid concentrations have 
been authorized by EFSA, whereas the claim released by 
FDA in 1999 is under debate as a result of more recent 
evidence.
5.8  Coenzyme Q10
In recent years, the coenzyme Q10 (CoQ10) has attracted 
scientific interest for its possible role on lipid profile.
A meta-analysis of RCTs showed that the consumption of 
CoQ10 at low doses (< 200 mg/day) significantly reduced 
serum triglycerides levels by 0.17 mmol/l, without affect-
ing other plasma lipids, in overweight and obese individuals 
with type 2 diabetes [82]. On the other hand, Sahebkar and 
colleagues, in a meta-analyses of seven RCTs, suggested a 
significant lowering effect of CoQ10 supplementation on 
plasma Lipoprotein-a (Lp(a)) levels, particularly in patients 
with baseline Lp(a) values ≥ 30 mg/dl. No change in the 
plasma concentrations of total cholesterol, LDL-choles-
terol, HDL-cholesterol and triglycerides was reported in 
this meta-analysis [83]. Findings from a more recent meta-
analysis including eight RCTs showed that taking CoQ10 
significantly decreased total cholesterol and increased HDL-
cholesterol levels in patients with coronary artery disease 
(CAD), without any effect on LDL-cholesterol, triglycerides 
and Lp(a) levels [84].
In conclusion, due to the limited clinical evidence, no 
conclusive indication can be given about the possible effi-
cacy of coenzyme Q10 supplementation on plasma lipids.
5.9  Combination of Nutraceuticals
The available evidence on the effect of fiber and phytosterol 
combination has shown a slightly higher cholesterol-lower-
ing action compared to the single components. Conversely, 
the combination of phytosterols and monacolin K did not 
provide any additional effect compared to the individual 
nutraceuticals [61].
A recent meta-analyses focusing on the effect of a 
nutraceutical comprising monacolin K (3 mg), berberine 
(500  mg), policosanols (10  mg), astaxanthin (0.5  mg), 
coenzyme Q10 (2 mg), and folic acid (200 μg) has shown 
that this combination reduced LDL-C (24 mg/dl) and TG 
(14 mg/dl), and increase HDL-C concentrations (2 mg/dl) 
[59].
6  Conclusions
The scientific evidence indicates a possible role of some 
nutraceuticals in the development of different CV risk fac-
tors (Table 1). This is also supported by evidence of the 
potential beneficial effects of single nutraceuticals and few 
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red yeast rice based combinations of nutraceuticals on sur-
rogate markers of CV risk, as vascular function [85].
Fiber, mainly the soluble/viscous type, seems to have 
beneficial effects on different CV risk factors even if the 
entity of these effects is not very high. Furthermore, LDL-
cholesterol levels are beneficially influenced by phytosterol, 
red yeast rice, and berberine, which seems to act positively 
also on blood glucose levels, plasma triglycerides, HDL-
cholesterol and blood pressure.
The effects of some types of polyphenols on different CV 
risk factors seem quite suggestive but there is urgent need 
for very well controlled intervention studies on large popu-
lations and for long periods of time, to be sure also of the 
safety aspect. Indeed, this is true for all nutraceuticals and 
applies also to the use of nutraceutical combinations. The 
clinical use of the combination of different nutraceuticals has 
become widespread, with the aim to act simultaneously on 
different CV risk factors and on the same risk factor through 
different mechanisms. However, also for this specific aspect 
we need to have more scientific evidence deriving from well-
controlled intervention studies, as required for drugs.
While awaiting such evidence, we can say that some nutra-
ceuticals may be useful in particular circumstances and in 
well-identified individuals, i.e. those at low-moderate CV risk 
who do not yet need drugs, or in addition to drug therapy—in 
line with what suggested by scientific societies. In any case, 
nutraceuticals should be taken under medical/nutritionist 
supervision. This last point is crucial since nutraceuticals, to 
be effective, should be taken regularly and at the recommended 
dosage.
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Table 1  Summary of the metabolic effects of nutraceuticals on body weight, blood pressure, blood glucose levels and plasma lipids
↓ Decrease, ↑ increase, – no effect, ? limited and variable data, NE not evaluated
Body weight Blood pressure Blood glucose levels Plasma lipids
LDL-c Triglycerides HDL-c















guar gum, HPMC, 
pectin)
– –
Polyphenols ↓/– (green tea cat-
echins)
↓ (resveratrol, cacao 
flavanols, soy 
isoflavones mainly 
in hypertensive and 
obese subjects)






? (tea and cocoa 
flavan-3-ols)
↓ green tea catechins
↓ Anthocyanins –
Omega-3 PUFA ? ↓ (in hypertensive 
subjects)
– (in diabetic sub-
jects)
– (↑ for doses > 4 g/
day)
↑ ↓↓ –
Phytosterol NE NE NE ↓ – –
Red yeast rice NE ? NE ↓↓ -
Berberine NE ↓ ↓ (in Asian popula-
tion)
↓ (in Asian popula-
tion)
↓ (in Asian popula-
tion)
↑ (in Asian 
popula-
tion)
Coenzyme Q 10 NE ? NE ? ? ?
Soy protein NE NE NE –/↓ (hyperlipidemic 
subjects)
NE NE
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